U.S. Markets closed

Biogen: Revenue Growth Is Expected in Q3

Mike Benson
Biogen: Revenue Growth Is Expected in Q3

As we discussed in the previous part, analysts expect Biogen’s (BIIB) revenues to increase 8.3% to $3.33 billion during the third quarter. Biogen’s product portfolio includes multiple sclerosis products, spinal muscular atrophy products, biosimilars, and other products. Biogen’s portfolio also includes Anti-CD20 therapeutic programs.